The $95.1M infusion and cash runway into 2029 remove near-term financing risk, but the massive warrant overhang (9.1M shares at $11.54) and mandatory S-3 resale registration will pressure the stock. Watch for the S-3 filing within 30 days and any insider selling patterns. DUET Phase 1b/2a initial data in H2 2027 is the next major catalyst.
Price Chart
Executive Summary
Surrozen closed the second tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds after FDA cleared the IND for SZN-8141. The company now has ~17.8M shares outstanding plus 12.9M shares issuable upon exercise of warrants and pre-funded warrants, extending cash runway into 2029 to fund the DUET Phase 1b/2a study and initial Phase 1b development of SZN-8143. The financing is a significant capital infusion for a pre-revenue biotech, but the substantial warrant overhang (9.1M shares) and planned S-3 resale registration create notable dilution risk.
Key Financial Metrics
Key Facts
- Second closing of March 2025 private placement generated ~$95.1M in gross proceeds.
- FDA cleared IND for SZN-8141 on October 2, 2026, triggering the second closing milestone.
- Second tranche included ~5.7M shares of common stock, pre-funded warrants for ~2.5M shares, and Series E warrants for ~4.1M shares.
- Post-closing: ~17.8M shares outstanding, 3.8M shares from pre-funded warrants, 9.1M shares from outstanding common stock warrants.
- Substantially all outstanding common stock warrants have an exercise price of $11.54 per share.
- Cash runway expected into 2029, funding DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b of SZN-8143.
- Company required to file S-3 resale registration statement within 30 days of closing.
- First patient dosing in DUET study expected Q4 2026; initial data expected H2 2027.
Financial Impact
~$95.1M gross proceeds from second tranche; total pro forma shares (including warrants) ~30.7M, representing significant potential dilution.
Risk Factors
- Substantial dilution from 9.1M outstanding warrants and 3.8M pre-funded warrants.
- Mandatory S-3 resale registration may lead to overhang and downward price pressure.
- Clinical risk: SZN-8141 and SZN-8143 are in early-stage development with no approved products.
- Cash runway into 2029 depends on no unexpected delays or cost overruns.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3385015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $25.48 | awaiting T+5 | — | $27.28 (+7.06%) |
Oct 20, 2026 6d ago | 8-K | $25.32 | awaiting T+5 | — | $27.28 (+7.74%) |
Oct 20, 2026 6d ago | Press Release | $25.32 | awaiting T+5 | — | $27.28 (+7.74%) |
Oct 7, 2026 18d ago | SC 13G/A | $27.97 $25.07 | ▼ −10.37% | ▼ −10.09% | $27.28 (−2.47%) |
Oct 2, 2026 24d ago | 8-K | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Oct 2, 2026 24d ago | Press Release | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Oct 1, 2026 25d ago | SC 13G | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Aug 7, 2026 11w ago | 25-NSE | $25.09 $23.78 | ▼ −5.22% | ▼ −5.17% | $27.28 (+8.73%) |
May 4, 2026 25w ago | Insider Cluster | $32.07 $29.28 | ▼ −8.70% | ▼ −11.64% | $27.28 (−14.94%) |
Mar 23, 2026 31w ago | S-3 | $25.00 $29.13 | ▼ −16.52% | ▼ −16.94% | $27.28 (−9.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers